Prognostic value of [(18)F]FDG-PET imaging in small cell lung cancer Journal Article
| Authors: | Pandit, N.; Gonen, M.; Krug, L.; Larson, S. M. |
| Article Title: | Prognostic value of [(18)F]FDG-PET imaging in small cell lung cancer |
| Abstract: | Positron emission tomography (PET) utilizing fluorine-18 fluorodeoxyglucose (FDG) has been used in the evaluation of non-small cell lung cancer (NSCLC). Recently its use in the staging of small cell lung cancer (SCLC) has been reported. However, the prognostic value of FDG-PET imaging in SCLC has not been studied. We performed a retrospective analysis to assess this, with the following hypotheses: (1) PET-positive patients would have a less favorable prognosis than PET-negative patients and (2) a high standardized uptake value (SUV) would be associated with a poor prognosis. Retrospective review of a mixed population of treated and untreated patients imaged between 1995 and 2000 was performed. Results of 62 scans in 46 patients were analyzed. There were 8 untreated and 38 treated patients. Findings were correlated with pathology, computed tomography/magnetic resonance imaging and clinical data. The sensitivity of PET scanning was 100% with pathological correlation. The prognostic value of a positive PET study was determined. Overall survival in PET-positive cases was significantly worse than that in PET-negative cases (P=0.0108). Correlation of SUVmax with survival showed a significant negative correlation (P=0.0021). In the eight untreated patients, scans were strongly positive and in all cases the scan results concurred with the final clinical stage assigned on the basis of conventional methods. We conclude that FDG-PET imaging provides prognostic information in treated patients. A positive study and a high SUVmax are significantly associated with poor survival. Additionally, FDG-PET may be helpful in staging and follow-up. |
| Keywords: | survival; adult; cancer survival; clinical article; controlled study; treatment outcome; aged; aged, 80 and over; middle aged; survival analysis; clinical trial; mortality; united states; comparative study; cancer staging; nuclear magnetic resonance imaging; positron emission tomography; follow up; methodology; follow-up studies; staging; neoplasm staging; laboratory diagnosis; sensitivity and specificity; radiopharmaceuticals; reproducibility; reproducibility of results; computer assisted tomography; controlled clinical trial; lung neoplasms; pathology; validation study; lung tumor; lung small cell cancer; correlation analysis; diagnostic agent; drug uptake; fluorodeoxyglucose f 18; computer assisted emission tomography; fluorodeoxyglucose f18; radiopharmaceutical agent; scintiscanning; pet; false positive reactions; false negative reactions; fdg; small cell carcinoma; small cell lung cancer; tomography, emission-computed; carcinoma, small cell; single blind procedure; single-blind method; suv; humans; prognosis; human; male; female; article |
| Journal Title: | European Journal of Nuclear Medicine and Molecular Imaging |
| Volume: | 30 |
| Issue: | 1 |
| ISSN: | 1619-7070 |
| Publisher: | Springer |
| Date Published: | 2003-01-01 |
| Start Page: | 78 |
| End Page: | 84 |
| Language: | English |
| DOI: | 10.1007/s00259-002-0937-8 |
| PUBMED: | 12483413 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | Export Date: 12 September 2014 -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
-
1028Gonen -
342Pandit-Taskar -
958Larson
Related MSK Work